| Document |
Document Title |
|
WO/2022/260062A1 |
The purpose of the present invention is to provide a method that is for producing p-toluenesulfonate of 7-(2,3-difluoro-4-(2-((2-methoxyethyl)(methyl)amino)ethoxy)b
enzyl)-10-hydroxy-6-methy-N-(4-methyl-2-(6-methylpyrimidine-
4-yl)phenyl...
|
|
WO/2022/260016A1 |
The present invention provides a compound that has a T-type calcium channel blocking effect and that is represented by formula (I) [in the formula, R1, R2, R3, R4, k, l, m, and n are as defined in the description] or a pharmacologically ...
|
|
WO/2022/255478A1 |
The purpose of the present invention is to provide a drug for treating prostate cancer including castration-resistant prostate cancer.　The problem can be solved by using this pharmaceutical composition for prostate cancer treatment, sa...
|
|
WO/2022/253326A1 |
The present invention relates to the technical field of medicine, and relates to an NLRP3 inflammasome inhibitor and an application thereof. The present invention particularly relates to a compound represented by general formula (I) or a...
|
|
WO/2022/256378A1 |
Provided herein are fixed-dose combinations comprising bempedoic acid and tolvaptan. Also provided herein are methods of treating autosomal dominant polycystic kidney disease (ADPKD) by administering a combination of bempedoic acid and t...
|
|
WO/2022/255760A1 |
The pharmaceutical composition of the present invention can effectively prevent or treat hypertension-accompanied diabetic nephropathy by blocking, suppressing, or delaying the onset of hypertension-accompanied diabetic nephropathy in ad...
|
|
WO/2022/253943A1 |
This present invention relates to crystalline form of 3-(5-Methyl-1,3-thiazol-2-yl)-5-[(3R)- tetrahydrofuran-3-yloxy]-N-{(1R)-1-[2-(trifluoro-methyl)pyri
midin-5-yl]ethyl}-benzamide which is the modification II, to processes for its prep...
|
|
WO/2022/253152A1 |
A 7-nitro-8-hydroxyquinoline derivative, a preparation method therefor and the medical use thereof. Specifically, disclosed are a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition conta...
|
|
WO/2022/256550A1 |
Forms of ethyl 3-ethyl-2,6-dioxo-1-propyl-8-(1-(3-(trifluoromethyl)benzyl)-
1H-pyrazol-4-yl)-1,2,3,6-tetrahydro-7H-purine-7-carboxylate,
designated herein as Compound I, were prepared and characterized in the solid state. Also provided ...
|
|
WO/2022/251359A1 |
The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.
|
|
WO/2022/250957A2 |
Provided herein are compounds, thioester prodrugs thereof, compositions, and methods for the treatment of diseases and disorders associated with renal anomalies.
|
|
WO/2022/251645A1 |
Provided are pharmaceutical compositions for intravenous administration comprising hyaluronidase and a vasodilator and methods of treatment and use thereof.
|
|
WO/2022/250108A1 |
The present invention pertains to a therapeutic agent or preventative agent against diseases involving an orexin receptor, particularly an orexin type-2 receptor, the agent containing a novel compound having a urea skeleton, or a pharmac...
|
|
WO/2022/251563A1 |
Described herein are ferric citrate-containing pharmaceutical compositions (e.g., solid oral dosage forms such as tablets). The pharmaceutical compositions described here can be administered to a subject in need thereof. In particular, t...
|
|
WO/2022/251060A2 |
The present invention includes methods and compositions useful for the treatment of Dent's disease in a subject in need thereof. The invention of the present disclosure also includes a mouse model useful for the study of Dent's disease.
|
|
WO/2022/244757A1 |
The present invention provides a pharmaceutical composition for treating or preventing a disorder associated with administration of an anticancer agent. The present invention relates to a pharmaceutical composition for treating or preven...
|
|
WO/2022/242533A1 |
A gel composition for improving the efficiency of calculus lithotripsy surgery of the urinary system and assisting in the removal of stone fragments in a kidney collection system. The gel composition comprises component A and component B...
|
|
WO/2022/246298A1 |
The disclosure provides a method of treating interstitial cystitis/bladder pain syndrome in a human subject in need of such treatment, comprising administering to the human subject a therapeutically effective amount of a compound of form...
|
|
WO/2022/242173A1 |
A traditional Chinese medicine for the treatment of diabetic nephropathy, comprising the following raw materials in parts by weight: 9-30 parts of radix astragali, 6-15 parts of semen cuscutae, 5-10 parts of peach kernel, 3-10 parts of r...
|
|
WO/2022/242782A1 |
The present application relates to a quinoline mercaptoacetate sulfonamide derivative, an intermediate, a pharmaceutical derivative or a formulation, and a preparation method and use therefor. The structure of the quinoline mercaptoaceti...
|
|
WO/2022/244846A1 |
The present invention provides a composition for regulating cell proliferation, said composition containing a regulator of D-amino acid content, or a composition that activates an mTOR-related pathway. The present invention also provides...
|
|
WO/2022/246200A1 |
Methods of treating proteinuric glomerular diseases are provided, including methods comprising administering a compound having structure (I), or a pharmaceutically acceptable salt thereof, to a subject in need thereof. In some embodiment...
|
|
WO/2022/244876A1 |
The purpose of the present invention is to provide a new antitumor agent. Specifically, the present invention uses, as an antitumor agent, T-cells expressing a T-cell receptor including a peptide represented by SEQ ID NO: 1 and a peptide...
|
|
WO/2022/237780A1 |
An amide derivative and the pharmaceutical use thereof, in particular, the present invention relates to an amide derivative of formula (I) or a pharmaceutically acceptable salt thereof or all stereoisomers, tautomers and deuterated compo...
|
|
WO/2022/241023A1 |
The application relates to triazole derivatives of the general Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The compounds are useful for the treatment of diseases and/or conditions th...
|
|
WO/2022/239714A1 |
[Problem] The purpose of the present invention is to provide an agent for preventing or improving nocturia, an agent for preventing or improving wakefulness after sleep onset, or an agent for preventing or improving frequent urination. [...
|
|
WO/2022/239755A1 |
Provided is a composition for increasing muscle mass in a mammal, the composition comprising a citric acid, a salt of a citric acid, a hydrate thereof, or a mixture thereof.
|
|
WO/2022/236814A1 |
The present invention provides a use of an alginate oligosaccharide or a pharmaceutically acceptable salt thereof in preparation of a drug for treating acute kidney injury. The alginate oligosaccharide is alginate disaccharide, alginate ...
|
|
WO/2022/237781A1 |
Provided are an amide derivative and an application thereof in medicine, in particular, an amide derivative as represented by formula (I), or a pharmaceutically acceptable salt thereof, or all stereoisomers, tautomers, and deuterated pro...
|
|
WO/2022/240079A1 |
The present invention relates to a pharmaceutical composition for preventing or treating a kidney disease, comprising glutathione as an active ingredient, and the present inventors have confirmed that, as a result of treating, with human...
|
|
WO/2022/240831A1 |
Methods for treating anemia are provided and include the steps of identifying a subject as having anemia characterized by a reduced number of red blood cells and then administering a polypeptide antagonist of a Na/K ATPase/Src receptor c...
|
|
WO/2022/240879A1 |
The application relates to pyrazole derivatives of the general Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The compounds are useful for the treatment of diseases and conditions inclu...
|
|
WO/2022/237890A1 |
An azepine-type fused ring compound and a pharmaceutical use thereof. Specifically, involved are an azepine-type fused ring compound shown in general formula (I), a preparation method therefor, a pharmaceutical composition comprising sam...
|
|
WO/2022/237843A1 |
A class of Axl inhibitors. Specifically, disclosed are novel compounds as represented by formulae (1), (2), (3), and (4) and/or pharmaceutically acceptable salts thereof, and a composition containing the compounds as represented by formu...
|
|
WO/2022/233302A1 |
The present invention provides a compound as represented by general formula (I), a cis-trans isomer thereof, an enantiomer thereof, a diastereomer thereof, a racemate thereof, a solvate thereof, a hydrate thereof, or a pharmaceutically-a...
|
|
WO/2022/234541A1 |
Described herein are methods of treating atypical hemolytic uremic syndrome (aHUS) with the Factor B inhibitor LNP023 (iptacopan) or a pharmaceutically acceptable salt thereof, e.g. iptacopan hydrochloride.
|
|
WO/2022/232163A1 |
Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synth...
|
|
WO/2022/229434A1 |
There are disclosed fusion proteins comprising an anti-CD3 antibody and an autoantigen involved in autoimmune diseases, nucleic acid encoding the same, pharmaceutical composition comprising them and the use thereof for the treatment of a...
|
|
WO/2022/230491A1 |
The purpose of the present invention is to provide a composition for ameliorating or suppressing the decline of kidney functions and a method for ameliorating or suppressing the decline of kidney functions. The present invention pertains...
|
|
WO/2022/228365A1 |
A derivative of a six-membered heteroaromatic urea ring represented by formula (I) and an application thereof in the preparation of a drug for treating diabetic nephropathy or hypertensive nephropathy.
|
|
WO/2022/227743A1 |
The present invention relates to the technical field of medicines, and provides a memantine urea derivative, a preparation method therefore, and an application thereof. The memantine urea derivative provided by the present invention has ...
|
|
WO/2022/222596A1 |
A prostate cancer treatment product, comprising deslanoside and adjuvants, the concentration of deslanoside is greater than or equal to 1 mg/kg and less than or equal to 10 mg/kg, and the adjuvants comprise medical ethanol, medical grade...
|
|
WO/2022/223428A1 |
The present invention relates to a mRNA and a therapeutic composition thereof for use in a method of treating lower urinary tract symptoms.
|
|
WO/2022/222972A1 |
A capsule for specific drug delivery and a preparation method therefor, relating to a capsule containing a non-liquid filler and a modified release coating. The modified release coating covers a capsule shell, an isolating layer is provi...
|
|
WO/2022/222205A1 |
Provided in the present invention are an amoxicillin capsule and a preparation method therefor, belonging to the technical field of drug preparation. 10-35 wt% of light amoxicillin powder with a particle size of less than 0.180 mm and 10...
|
|
WO/2022/222248A1 |
A method for preparing a medicinal liquor having the functions of invigorating the spleen and tonifying the kidney. The method comprises the following steps: 1) soaking the medicinal materials of Glycyrrhizae radix et rhizoma, Carthami f...
|
|
WO/2022/222730A1 |
Disclosed in the present invention are a compound with mother nucleus of 3-phenyl-1,2,4-oxadiazole, a preparation method therefor and an application thereof. The compound with mother nucleus of 3-phenyl-1,2,4-oxadiazole provided in the p...
|
|
WO/2022/222899A1 |
An application of pectin in preparation of health-care products and drugs, comprising health-care products or drugs for improving/reversing chronic kidney diseases caused by virus or drug damage, and health-care products or drugs for cur...
|
|
WO/2022/225007A1 |
The present invention addresses the problem of providing an actinium-225-labeled anti-MUC5AC humanized antibody exhibiting excellent specificity to mucin subtype 5AC (MUC5AC), excellent clustering in tumors, and reduced kidney toxicity. ...
|
|
WO/2022/226166A1 |
Provided herein are compounds of formula I that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the c...
|
